In early development, speed is everything. Programs are designed to move quickly—to generate clinical material, reach the clinic, and prove the molecule is safe and efficacious. As the programs enter pivotal phase, the equation fundamentally changes.
The question is no longer “Can we make this molecule?” It becomes: “Can we make it consistently, at scale, and with robust manufacturing process with scale enough to supply commercial demand—without risking the asset?”
This shift—from speed to reproducibility, robustness, and risk mitigation—is where many programs succeed… or quietly struggle. For sponsors approaching Late-Phase development, selecting the right CDMO is one of the most consequential decisions they will make.
The right partner doesn’t just manufacture product—they help ensure the program can withstand the demands of commercialization.